Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis
Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.
You may also be interested in...
The view from 2020: Scrip looks back at the most successful commercial launches of the decade.
Biogen Idec’s Tecfidera, on track to generate more than $1 billion in sales its first 12 months on the market, was the exceptional drug launch of 2013, in a year that included few breakout stars.
Companies discuss their plans to move pipelines forward as the third quarter wraps up and they prepare for new launches and new indications in the coming year.